We are committed to expanding our portfolio and our pipeline in therapeutic areas that can leverage our unique expertise and growing our global footprint.
At Jazz, our focus is on innovating to transform the lives of patients. We develop and commercialize life-changing medicines to transform the lives of people with serious diseases —so they can live their lives more fully. We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic and solid tumors. We believe patients, even small groups of patients, living with complex conditions deserve solutions. We work every day to expand the science behind our therapies, acquire new medicines, or partner with other industry leaders to advance molecules with great potential.
For more than 15 years, Jazz has been at the forefront of sleep medicine. We have long understood that sleep disorders can impact every facet of someone’s life. For many people with these conditions, there were no approved treatments until Jazz made one available. Many patients affected by serious sleep disorders still need options, which is why we have focused our resources on identifying and developing these therapies.
Our novel medicines help people to enjoy small victories every day and we are using everything we have learned as a leader in sleep medicine to broaden our focus within neuroscience. Today our development focus includes sleep, essential tremor and PTSD. Learn more about our R&D.
Hematology and Oncology
Jazz has a growing hematology and oncology therapeutic area – with a focus in the areas of relapsed small cell lung cancer, acute leukemias, both lymphocytic and myeloid (ALL and AML) and for patients who develop an ultra-rare complication of hematopoietic stem cell transplantation (HSCT), known as veno-occlusive disease (VOD).
While the hematology and oncology community is large, we focus on smaller groups of people facing unique challenges and difficult odds. We have made significant strides in growing our oncology portfolio, which now includes commercial and investigational therapies for hematology malignancies and solid tumors at all stages of development. Learn more about our R&D.
Learn more about Our Medicines.